13ᵗʰ International Symposium on Hodgkin Lymphoma
back to
back to
Program
Schedule
26.10.2024
27.10.2024
28.10.2024
Scientific Committee
Media
Photos
Videos
Downloads
Abstracts
Newsletters
Acknowledgements
Sponsors
Other Archives
ISHL13
ISHL12
Update on Hodgkin Lymphoma
ISHL11
ISHL10
ISHL9
ISHL8
ISHL7
Back to video list
Development and application of a validated MRD assay in Hodgkin Lymphoma
Speaker
Julia Mattlener
Session
Advanced Stages
Others Talks of this Session
Individualized treatment de-escalation improves overall outcomes
Immune-chemotherapy overcomes the need for individualization
2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS
Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials
This website uses cookies to ensure you get the best experience on our website. By using our site you agree to our use of cookies.
Learn more
Got it!